anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Drugs that inhibit the renin-angiotensin system can cause hyperkalemia.  
Concomitant use of ATACAND with drugs that increase potassium levels may increase the risk of hyperkalemia [see Drug Interactions (7.1)].

Monitor serum potassium periodically.

In the CHARM program (heart failure patients), the incidence of hyperkalemia was 6.3% in patients treated with ATACAND versus 2.1% in patients treated with placebo. The incidence of hyperkalemia leading to drug discontinuation in ATACAND-treated patients was 2.4% compared with 0.6% in placebo-treated patients. In the CHARM-Added program where candesartan or placebo was given in addition to ACE inhibitors, the incidence of hyperkalemia was 9.5% in patients treated with ATACAND versus 3.5% in patients treated with placebo [see Drug Interactions (7.1)].
PURPOSE:To enhance the probability by which an area, etc., interested by a doctor who executes a diagnosis are brought to image processing optimally by storing correspondingly a disease name and an image processing condition, and performing the image processing to image data, based on the image processing condition corresponding to the disease name being a diagnostic object. CONSTITUTION:In an image processing condition storage part 1, various disease names considered as a diagnostic object and an image processing condition corresponding to each disease name are stored. Image data S1 being an object of an image processing for showing a medical image is inputted to an image processing part 2. Also, simultaneously therewith or about simultaneously therewith, with regard to the medical image corresponding to the image data S1, the disease name being a diagnostic object is informed to the storage part 1, and from the storage part 1, an image processing condition P corresponding to the disease name concerned is inputted to the image processing part 2. In the processing part 2, in accordance with the inputted condition P, the image processing is performed to the image data S1 and image data S2 whose image processing is ended is generated. The data S2 is sent to an image reproducing device and a visible image based on this data S2 is reproduced and displayed, or sent to an image storage device.
An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1. Recombinant expression vectors comprising the chimeric GLP-1 nucleic acid sequences, which produce GLP-1 constitutively are provided, as are human cells transfected with such an expression vector in combination with an expression vector comprising a proinsulin nucleic acid sequence and an expression vector comprising a furin and a glucose-regulatable TGF-alpha promoter. Methods of producing human GLP-1 constitutively are provided as are method of producing GLP-1 and insulin or in a glucose-dependent manner using such transfected cells. Methods of treating a subject having Type II diabetes and methods of treating a subject prone to hyperglycemia or suffering from hyperglycemia are provided in which transfected cells produce human GLP-1 and insulin in a glucose-dependent manner. Also provided are methods of reducing weight in a subject by implanting into the subject transfected cells which produce human GLP-1 and insulin in a glucose-dependent manner.
Insulin therapy:If post meal (2 hours after meal) glycaemia is \> to 120 mg/dl introduce Insulin rapid acting analog (Humalog\*, Novorapid\*) before the meal concerned and according to the weight. If weight is \< 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is \> 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping : 5U if weight is \< 80 kg - 6U if weight is \> 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
The invention discloses medicinal oil for treating exfoliative dermatitis and a preparation method thereof. The medicinal oil is prepared from the following raw materials by weight: 100-300g of angelica sinensis, 100-300g of radix paeoniae alba, 100-300g of dried radix rehmanniae, 100-300g of radix scrophulariae, 100-300g of cortex moutan, 100-300g of polygonatum odoratum, 100-300g of radix lithospermi, 100-300g of tribulusterrestris, 100-300g of cortex dictamni, 100-300g of fructus kochiae and 1000g-3000g of sesame oil. The preparation method of the medicinal oil comprises the following steps of firstly adding the angelica sinensis, the radix paeoniae alba, the dried radix rehmanniae, the radix scrophulariae, the cortex moutan, the polygonatum odoratum, the radix lithospermi, the tribulusterrestris, the cortex dictamni and the fructus kochiae to the sesame oil, soaking for 5 days, then heating and frying the medicines to black brown, fishing out decoction dregs at 100-150 DEG C, cooling the medicinal oil, and subpackaging in plastic bottles for later use. The medicinal oil has the beneficial effects that the medicinal oil is a pure traditional Chinese medicine preparation and is used for treating the exfoliative dermatitis. The medicinal oil has the most prominent characteristics that after being applied on a diseased region, the medicinal oil plays a role in nourishing blood, promoting blood flow, clearing heat, nourishing yin and moistening skin, dispelling wind and relieving itching and is harmless to skins and convenient to use. Compared with other external medicines, the medicinal oil has certain superiority and practicability.
Participants 4 to \<6 months of age and weighing greater than or equal to (≥) 5 kg received 25 mg IVA q12h. At 6 months of age and older, participants weighing 5 to \<7 kg received 25 mg IVA, 7 to \<14 kg received 50 mg IVA, and those weighing 14 to \<25 kg received 75 mg IVA q12h for 24 weeks on Part B. For Part A/B, participants 1 to \<4 months weighing 3 kg to \<5 kg received an initial low dose of 5.7 mg q12h IVA and those weighing ≥5 kg received 11.4 mg q12h IVA for the first 15 days of IVA treatment. Doses were maintained or adjusted upward at Day 15 and based on weight and/or age once they reached 4 months of age.
In the IVC USG group, USG assessment and volume optimisation using collapsibility index will be done prior to spinal anaesthesia. all patients will be lying supine, for at least 5 min before IVC examination. Ultrasound measurements will be performed using a Sonosite M-Turbo (Sonosite Inc., USA) machine and phased array 5-1 Megahertz transducer (Sonosite Inc.) set to abdominal mode by an M-mode modality through the subcostal view. All IVC measurements will be performed by principal investigator before spinal anaesthesia. Principal investigator should have performed more than 25 scans before the commencement of the study.
Children with a diagnosis of iron deficiency anemia. Patients who received standard therapy (Fe preparations) 3 mg/kgBW/day and received standard therapy combination vitamin D, 400 IU for 4 weeks, were then checked again for complete blood count, serum fe, and serum ferritin.
PROBLEM TO BE SOLVED: To use a specific methacrylic acid copolymer as a disintegrating agent or an assistant in a tablet for obtaining an easily producible galenical type tablet, having an excellent cohesive power and a rapid disintegrating rate. SOLUTION: This C-type methacrylic acid copolymer according to the American Pharmacopeia and the National Formulations (e.g.; a compound of the formula) is used as a disintegrating agent or an assistant in a tablet, preferably as a rapid disintegrating agent or an instant type rapid disintegrating agent. Further, one or more of other disintegrating agents such as cross-povidone, etc., are preferably used. The above tablet is preferably aimed at the oral administration and the disintegration in an oral cavity. The above polymer is preferably integrated in a lump material of the tablet, or one or more of the lower part structures of the tablet such as micro-particles of the tablet, a micro-capsule, a layer in the tablet, etc. It is preferable that the above lump material or the lower structure can be changed into a galenical shape by a direct compression.
The tonic contains an alcoholic extract of (a) avena sativa (oats) and (b) fructus vitis viniverae (dried grapes). The pref. variety of oats is flores avenae. The panicle of green oats is used. The grapes are pref. white, unbleached Californian sultanas. The weight ratio of (a):(b) is 0.1-10 (pref.  0.5-5). The tonic may also contain extracts of foeniculum vulgare (fennel). USE/ADVANTAGE - In the treatment of frigidity or reduced libido in women. The tonic also has a calming and relaxing effect. It increases circulation, thus contributing to a reduction in internal swelling.
TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
This is a single-arm open label mechanistic clinical trial. Subjects will be treated with rosuvastatin at a dose of 20mg/day and uptitrated as tolerated to a dose of 40mg/day.
Families in the staggered intervention arm will serve as controls for the first intervention arm during Fall 2019. Families the staggered intervention arm will then participate in the HEROs intervention in Spring 2020.
Thirty participants randomly allocated to group 1. All the participants received a pressure biofeedback guided deep cervical flexor muscle strength training along wth conventional intervention.
The present observational study has the objective to reevaluate at distance the cohort of 67 children with sickle cell anemia enrolled in the "Drepagreffe"trial because of cerebral vasculopathy detected by transcranial Doppler. Results at 1 and 3 years were reported in JAMA in 2019 in BHJ in 2020. This trial was the first worldwide prospective study comparing transplantation to standard care in sickle cell disease. Velocities were highly significantly more reduced with a higher proportion of patients with normalized velocities and better quality of life after transplantation than on standard care. Despite a trend to a better ischemic lesions outcome at 3 years, the difference was not significant and cognitive performances were not different between both groups. The biologic study only assessed at enrollment and 1-year showed lower levels of Ang-2 and HGF (hepatocyte growth factor) after transplant and a significant and independent association between Doppler normalization probability with low Ang-2 and BDNF (brain-derived neurotrophic factor) levels.The aim of the present study is to reassess at 9-10 years this cohort with grants allowing to reevaluate cognitive functioning and hypoxia/angiogenic factors not realized in the systematic cohort follow-up
For this first study, we will inject the PNP-loaded adenovirus into the tumors of patients with cancers primarily in the throat and neck and then give them the drug. This study is designed with two goals in mind: 1) assessing the overall safety of this approach for the patient; and 2) observing the effects of this anti-cancer strategy on the tumor itself. This will be accomplished in two parts. First, we will introduce a modest, fixed amount of the gene-carrying adenovirus into the tumors of three separate groups of patients and then administer small, increasingly strong amounts of the fludarabine phosphate to each successive group over a three-day period. Even in the group that will receive the highest amount of fludarabine, the total amount given to any individual patient over those three days will be significantly less than the dose approved by the FDA for patients with non-solid tumors. Finally, a more concentrated amount of the adenovirus (approximately 10 times more viruses) will be given to a fourth group of patients who will also receive the highest dose of the drug that was shown to be well tolerated in the prior three groups (the highest dose at which no serious problems were observed).
Few studies have examined neural correlates of late talking in toddlers, which could aid in understanding etiology and improving diagnosis of developmental language disorder (DLD). Greater frontal gamma activity has been linked to better language skills, but findings vary by risk for developmental disorders, and this has not been investigated in late talkers. This study examined whether frontal gamma power (30-50 Hz), from baseline-state electroencephalography (EEG), was related to DLD risk (categorical late talking status) and a continuous measure of expressive language in n = 124 toddlers. Frontal gamma power was significantly associated with late talker status when controlling for demographic factors and concurrent receptive language (β = 1.96, McFadden's Pseudo R2 = 0.21). Demographic factors and receptive language did not significantly moderate the association between frontal gamma power and late talker status. A continuous measure of expressive language ability was not significantly associated with gamma (r = -0.07). Findings suggest that frontal gamma power may be useful in discriminating between groups of children that differ in DLD risk, but not for expressive language along a continuous spectrum of ability.
BACKGROUND: The aim of this single-center study was to evaluate the early results of the off-the-shelf inner branch E-nside endograft in the treatment of complex aortic aneurysms and thoracoabdominal aortic aneurysms.
METHODS: We performed a retrospective analysis of a prospectively maintained database of all patients treated with the E-nside endograft at our institution during the years 2021-2023. Parameters evaluated were technical success, early major adverse events, target vessel patency, and the presence of endoleaks.
RESULTS: In total 16 patients underwent treatment with the E-nside endograft. Six additional patients were evaluated for the device but were excluded due to anatomical considerations. Mean age was 71 (range 59-84) and 14 (88%) were males. Mean aneurysm diameter was 66 mm (range 54-85). Aneurysms treated included thoracoabdominal in 9 (56%), juxtarenal aneurysms in 5 (31%), postdissection aneurysm in 1 (6%) and a type 1A endoleak after a failed endovascular aneurysm repair in 1 (6%). Five of the treated aneurysms were symptomatic. A total of 58 side branches were placed into target visceral arteries. Mean operative time was 190 min (range 150-360). Technical success was achieved in 15/16 of the patients (94%). At 30 days, 1 perioperative mortality and 3 major adverse events occurred, 2 of them branch related.
CONCLUSIONS: The E-nside endograft is a feasible option for the treatment of a broad spectrum of aortic pathologies. As it is an off-the-shelf device, it can be used selectively in elective and emergent settings with acceptable 30-day mortality and morbidity. Further follow-up is required to determine the durability of this treatment option and patency of side branches.
CK-E is a G-CBT treatment developed specifically for treatment of youth SAD. The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session.
The invention relates to a traditional Chinese medicine composition for treating senile tinnitus. The traditional Chinese medicine composition comprises the following bulk drugs of, by weight, 10-20 parts of suncured ginseng, 1-5 parts of cornu cervi, 20-30 parts of mulberries, 15-20 parts of radix polygoni multiflori preparata, 15-25 parts of magnets, 20-30 parts of fossil fragments, 15-30 parts of spina date seeds, 15-25 parts of bupleurum, 15-25 parts of rust-brown crotalaria, 15-25 parts of liquidambar formosana hance, 10-20 parts of earthworms and 1-5 parts of leeches. The drugs are mixed, water is added to the drugs for immersion, water and the drugs are decocted two times, and filter liquor obtained at two times is combined and evenly mixed. Twelve traditional Chinese medicine components are selected for the drugs, the suncured ginseng paste serves as a monarch drug, the cornu cervi, the mulberries and the radix polygoni multiflori preparata raise yang and enrich yin and are ministerial drugs, the fossil fragments, the spina date seeds, the bupleurum and the rust-brown crotalaria relieve convulsion, soothe the nerves, nourish yin and soothe the liver and are adjuvant drugs, the liquidambar formosana hance, the earthworms and the leeches promote blood circulation to remove meridian and are adjuvant drugs, the magnets are a guiding drug, the drugs reach disease positions, and the drugs are used in a combined mode and have the effects of tonifying qi, nourishing the kidneys, and soothing the liver and dredging collaterals, namely, reinforcing the vital essence and dredging the collaterals. The traditional Chinese medicine composition is used for treating finnitus due to the kidney deficiency and has the obvious definite curative effect from the aspect of preventing or treating the senile tinnitus. The traditional Chinese medicine composition is stable in curative effect, good in effect, fewer in side effect, low in cost and innovative in drug for treating the senile tinnitus.
Suicidal ideation or attempts occurred more frequently among pediatric patients compared to adult patients (2.4% versus 1%) during treatment and off therapy follow-up (see WARNINGS). As in adult patients, pediatric patients experienced other psychiatric adverse events (e.g., depression, emotional lability, somnolence), anemia, and neutropenia (see WARNINGS). During a 48 week course of therapy there was a decrease in the rate of linear growth (mean percentile assignment decrease of 7%) and a decrease in the rate of weight gain (mean percentile assignment decrease of 9%). A general reversal of these trends was noted during the 24 week post treatment period.

Injection site disorders, fever, anorexia, vomiting, and emotional lability occurred more frequently in pediatric patients compared to adult patients. Conversely, pediatric patients experienced less fatigue, dyspepsia, arthralgia, insomnia, irritability, impaired concentration, dyspnea, and pruritis compared to adult patients.
Lumbar hernias are a relatively uncommon occurrence, with two main categories: congenital and acquired. Some acquired hernias are spontaneous, while others are the result of secondary factors such as trauma and surgery. Bilateral primary lumbar hernia is a much rarer occurrence. Abdominal computed tomography is the gold standard for differential diagnosis of bilateral primary lumbar hernia. The treatment plan entails the closure of the defect through either open or laparoscopic methods, accompanied by the use of a suitable mesh to provide support. Nevertheless, no surgical method has yet been identified as the standard procedure for reducing the risk of relapse. We present the case of a 73-year-old female patient who presented with complaints of swelling in the left lumbar region and abdominal pain. The patient exhibited bilateral lumbar hernia. The hernial sac on the left side contained intra-abdominal organs. The diagnosis was confirmed by computed tomography. The defect on the left was subsequently closed with mesh following the dissection of the hernia sac. In this study, we present a case of bilateral lumbar hernia in the context of existing literature. The objective of this study was to assist clinicians in accurately diagnosing and appropriately managing this condition.
In 2008 our group published the results of a multicentre, randomized, double-blinded study comparing standard radiotherapy to breast IMRT. The study showed a significant reduction moist desquamation using breast IMRT from 47.8% to 31.2% (p=0.002). There are two other Phase III trials showing improvement of long term cosmetic outcomes. Yet the use of breast IMRT remains not widely accepted. This trial aims at evaluating long term tolerance of breast IMRT compared to standard radiotherapy.

The investigators hypothesize that breast IMRT reduces the occurence of chronic breast pain (primary objective), improves cosmesis, reduces the occurence of delayed and permanent radiation induced skin side effects (telangiectasia, dryness, induration, edema, discolorations), improves quality of life. The investigators also hypothesize that there will not be differences in the local control rate or survival.
Excessive daytime sleepiness is responsible of 20% of traffic accidents and 2/3 of truck accidents on French Freeways. Since the publication of a new law (arrêté du 28 décembre 2005 du journal officiel) regulating fitness to drive, the Maintenance of Wakefulness Test (MWT) is now mandatory to evaluate driving skills of patients suffering of excessive daytime sleepiness. The MWT has shown a good predictability of driving handicap on simulators in patients suffering from obstructive sleep apnea syndrome. Nevertheless no study has proven yet the predictability of the MWT regarding real and simulated driving in narcoleptics and hypersomniacs. Furthermore, even if alerting drugs significantly improve MWT scores there is no data available concerning the impact of these drugs on fitness to drive. This lack of knowledge is a major handicap to evaluate driving skills of treated patients suffering from excessive daytime sleepiness. The main objective of our project is to test the predictive value of the MWT on real and simulated driving performances in untreated and treated sleepy patients suffering from narcolepsy and hypersomnia. Inclusion of healthy volunteers will allow to collect reference data about somnolence during MWT.
Blincyto is given over a 28-day cycle. Starting day for patients, who are MRD-positive before HSCT is between day +60 and day +100 and for patients, who become MRD-positive post HSCT it is between day +60 and day +360 post HSCT.
Participants will exercise at 60% maximum heart rate for 15 minutes. This heart rate will be calculated by taking 220-age (in years) and multiplying by 0.6 to determine the target heart rate while performing the low level aerobic exercise. Aerobic exercises may include treadmill, walking or stationary cycling. Exercise will be performed 5-6 times per week independently at home and monitored by their parents. Individuals will be taught how to monitor their heart rate. This protocol has previously been found to be feasible and of minimal risk to participants.
PURPOSE:To obtain the titled preventive agent, containing cholera toxins as an active ingredient and capable of exhibiting particularly improved effects on prevention of rejection. CONSTITUTION:A preventive agent containing cholera toxins which are proteins, produced by a Gram-negative bacterium Vibrio cholerae, having about 84,000mol. wt. and consisting of one subunit (A) having about 27,000mol.wt. and 5 subunits (B) having about 11,600mol.wt. as an active ingredient. Even toxins having a partially deformed structure of the cholera toxins, e.g. amino acids are partially removed or added, and immunosuppressive activity are effectively used as the active ingredient. The administration route is preferably a route without passing through intestines and the does at a time is within the range of 0.5-50mug/kg.